- Tytuł:
- Effectiveness of novel iron regulators in the treatment of diabetic nephropathy
- Autorzy:
-
Banerjee, Dekai
Kaur, Ginpreet
Chatterjee, Bappaditya
Joshi, Hemant
Ramniwas, Seema
Singh Tuli, Hardeep - Powiązania:
- https://bibliotekanauki.pl/articles/29519511.pdf
- Data publikacji:
- 2023-09-30
- Wydawca:
- Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
- Tematy:
-
acute kidney injury
chronic kidney disease
end-stage renal disease
iron chelators
renal iron handling - Opis:
- Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.
- Źródło:
-
European Journal of Clinical and Experimental Medicine; 2023, 3; 639-647
2544-2406
2544-1361 - Pojawia się w:
- European Journal of Clinical and Experimental Medicine
- Dostawca treści:
- Biblioteka Nauki
Artykuł